Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin +/- Toripalimab in HR+/HER2-Low Breast Cancer
NCT06105008Phase 2Withdrawn
- Sponsor
- RemeGen
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Disitamab Vedotin + Toripalimab with Disitamab Vedotin (2 arms). Primary endpoint: Progression-free survival at 36 months. Planned start Dec 2024; status: withdrawn.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06105008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105008.